Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBaylor Scott & White Health Plan Genetic Testing C…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 037

    Genetic (Genomic) Testing Coverage Criteria

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 037 alerts

    Get alerted when Policy 037 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, documentation, and coverage criteria for genetic and genomic testing for members of Baylor Scott & White Health Plan and affiliated lines of business.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyGenetic (Genomic) Testing Coverage Criteria
    Policy CodePolicy 037
    Change TypeNo material changes
    Effective Date05/01/2026
    Last ReviewApr 23, 2026
    Next Review Date04/23/2027
    Key ActionComplete the SWHP Genetic Testing Prior Authorization Form with clinical justification and required documentation, including evidence of pre- and post-test genetic counseling.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Prior authorization requiredPA requirement
    Once per lifetimeTesting frequency limit
    Genetic counseling requiredCounseling requirement
    CLIA & FDALab/regulatory
    037Policy ID
    SWHP Genetic Testing PA FormPA form

    Coverage Criteria

    General medical necessity criteria — Covered when ALL of the following are met.

    Covered when ALL of the following are met:

    ALL of the following

    • Appropriate genetic counseling occurs before and after testing. Counseling must be by a practitioner with expertise in the genetic aspects of the condition being evaluated and who will discuss the results and clinical implications.

      Documentation of counseling must accompany the preauthorization request. Evidence should include discussion of possible results (positive, negative, uncertain), test limitations, risk evaluation, inheritance patterns, informed consent, and a plan for post-test counseling. Counseling must not be performed by practitioners employed by testing companies due to conflict of interest.

    • There is a reasonable expectation, based on family history, three-generation pedigree (where appropriate), risk factors, and/or symptomatology, that a genetically inherited or acquired condition exists or the member is at direct risk of inheriting the mutation (pre-symptomatic).

      A three-generation pedigree MUST accompany the request where appropriate.

    • Knowledge of the presence or absence of the condition would directly affect medical care of the member.

      The disease must be treatable and/or preventable, and the test results must lead to a change in surveillance frequency and/or treatment intensity for that disease.

    • The requested test is the smallest, most targeted study expected to answer the clinical question (single-gene test preferred when appropriate; panels allowed only when multiple genes plausibly explain the disorder).

      Multigene panels must list included genes and rationale; broad panels are not medically necessary when a focused test is available. Multiple panels tested concurrently are not medically necessary.

    • The test is performed in a CLIA-certified laboratory, is FDA-approved when applicable, and is recommended by recognized national guidelines.

      When possible, testing should be performed at a contracted/network laboratory. If a non-contracted lab is used, the provider must document the need and inform the member of potential out-of-pocket differences.

    • The request is submitted with the Baylor Scott & White Health Plan 'Statement of Medical Necessity for Genetic Testing' or equivalent documentation that answers the required justification questions and clearly explains how results will improve or change medical management.

      A generic statement that a test 'is medically necessary' is insufficient; the request must state specific changes in management or surveillance that would occur with positive or negative results.

    • Testing frequency limits are respected (generally once per lifetime for a specific mutation or panel, or once per pregnancy for prenatal testing), unless justified by changed guidelines or need for reinterpretation of results.

      Exceptions may be considered with supporting rationale.

    Specific test guidance — Tests with specific policy guidance.

    Tests with specific policy guidance:

    ALL of the following

    • Cell-free DNA screening tests for microdeletions (CPT 81422) are NOT medically necessary.
    • Whole genome sequencing may be medically necessary in clinically affected neonatal and pediatric patients to identify or confirm a genetic etiology when targeted studies have failed.

      In most cases whole genome sequencing will not be found medically necessary unless more targeted studies have failed to identify a mutation.

    Coverage contingent on completed prior authorization and clinical justification.

    Coverage is contingent on completion of prior authorization and provision of clinical justification. Requests must include answers to the clinical justification questions below and supporting documentation.

    ALL of the following

    • A completed prior authorization is required before testing is performed.

      Preauthorization must include documentation described in this policy (counseling documentation, pedigree when appropriate, laboratory information, and Statement of Medical Necessity or equivalent).

    • Provider must justify the clinical indication for each requested test by addressing the specific questions in the Statement of Medical Necessity or the provided Medical Information form.

      Required questions include: why the test is appropriate; whether the beneficiary exhibits clinical features or a family member has an identified variant; evidence of informed consent and genetic counseling; scientific validity of the test; willingness to undergo potential interventions; how results will specifically alter medical management; test cost; and whether a multigene panel is more cost-effective than individual tests.

    • Requests lacking required justification, pedigree, evidence of counseling/informed consent, or a clear explanation of how results will change management are subject to denial.

    Predictive/diagnostic/prognostic testing when reasonable expectation based on family history/pedigree/risk/symptoms that a genetic condition exists and results will directly affect medical management.

    Predictive/diagnostic/prognostic testing — Covered when:

    ALL of the following

    • There is reasonable expectation based on family history, pedigree, risk factors, and/or symptoms that a genetic condition exists and testing results will directly affect medical management.

      A three-generation pedigree must accompany requests where appropriate.

    Whole genome sequencing in clinically affected neonatal and pediatric patients when targeted studies have failed.

    Whole genome sequencing —

    ALL of the following

    • May be medically necessary in clinically affected neonatal and pediatric patients when more targeted studies have failed to identify a mutation.

      Whole genome sequencing is generally not medically necessary unless targeted testing has been unsuccessful.

    Requirement that provider justify clinical indication for each requested test per listed questions; must document how results will alter management and provide references.

    Provider must justify clinical indication for each requested test by answering the following and providing supporting references where applicable:

    ALL of the following

    • Why is the test appropriate for the patient?
    • Does the beneficiary exhibit clinical features of the mutation in question? If not, has a genetic variant been identified in a family member?
    • Has the patient given informed consent to the genetic test?
    • Has genetic counseling been provided?
    • What is the scientific validity of the testing? Provide references or links.

    There are no additional explicit exclusions in this section beyond those listed; requests missing required clinical justification or documentation may be denied as outlined above.

    Coding and Frequency Limits

    Genetic Test CPT/Procedure Codes with PA specificationsCPT
    81161DMD (dystrophin) deletion/duplication analysis
    81220CFTR gene analysis; common variants
    81221CFTR gene analysis; known familial variants
    81222CFTR gene analysis; duplication/deletion variants
    81223CFTR gene analysis; full gene sequence
    81224CFTR intron 8 poly-T analysis
    81229Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities
    81238F9 gene analysis (hemophilia B)
    81243FMR1 gene analysis (fragile X)
    81259HBA1/HBA2 gene analysis (alpha thalassemia)
    1–10 of 19
    1/2
    Notes on code applicabilitymixed
    No codes listed
    Form placeholders for ICD-10 and CPT codesmixed
    ICD-10 Codes:Placeholders on form for diagnosis codes supporting the test request
    CPT Code, 1 = Test. CPT Code, 2 = CPT Code. CPT Code, 3 = Test.Placeholders on form for CPT codes associated with requested genetic tests
    Testing frequency limit
    Frequency limitMost genetic/genomic testing is limited to once per lifetime (or once per pregnancy for prenatal testing); exceptions possible based on clinical need.
    ScopeApplies to most hereditary single-gene tests, multigene panels, and genomic tests unless otherwise specified.
    Prenatal notePrenatal testing may be limited to once per pregnancy.
    Documentation for exceptionsRequests for testing more than once require documented medical necessity and justification in the prior authorization request.

    Provider Actions & Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required — Genetic/genomic testing (including specific CPT/HCPCS codes) requires prior authorization. Requests must include the diagnosis and clinical documentation supporting medical necessity. Use the SWHP Genetic Testing Prior Authorization Form for submission.

    • PA required for listed genetic test CPT/HCPCS codes (see policy code list)
    • Include diagnosis and documentation with PA request
    • Use SWHP Genetic Testing Prior Authorization Form
    Prior Authorization

    Submit SWHP Prior Authorization Form

    Submit the SWHP Genetic Testing Prior Authorization Form (most recent version) with each request. The form captures member and provider identification, supplying provider details, requested test(s), ICD-10 and CPT codes, and a dedicated Medical Information section that must be completed to justify each test.

    • Form fields required: member name, SWHP ID, DOB, gender

    Eligibility Requirements

    Where appropriate, requests for genetic testing must be accompanied by a three-generation pedigree to support family history and risk assessment. Coverage decisions will be based on the documentation provided (pedigree, clinical notes, responses on the prior authorization form) demonstrating that testing meets the medical necessity criteria.

    No additional top-level eligibility exceptions are specified in this policy segment. Eligibility for coverage is determined by the medical necessity criteria and the documentation supplied with the prior authorization request.

    The prior authorization form explicitly asks whether a familial variant has been identified and requests justification of clinical features when the patient does not exhibit phenotype. Providers must answer these form questions and supply clinical rationale; the policy does not establish any universal eligibility exceptions in this segment—each request is evaluated based on the completed form and supporting documentation.

    Definitions

    First‑degree relative definition
    DefinitionFirst-degree relative: a blood relative with whom an individual shares approximately 50% of his or her genes, including parents, full siblings, and children.
    ExamplesParents, full siblings, children.
    RelevanceUsed to determine family risk when assessing clinical indication for genetic testing.
    Second‑degree relative definition
    DefinitionSecond-degree relative: a blood relative with whom an individual shares approximately 25% of his or her genes, including grandparents, grandchildren, aunts, uncles, nephews, nieces, and half-siblings.
    ExamplesGrandparents, aunts/uncles, nieces/nephews, half‑siblings.

    Not Covered / Not Medically Necessary

    Not covered: Genetic testing performed solely for non-medical purposes (including paternity, ancestry testing, GWAS, and non-disease trait testing), and routine or ongoing long-term genetic counseling services are examples of services that will not be authorized under this policy.

    Not covered: Cell-free DNA microdeletion screening (CPT 81422) is specifically stated as not medically necessary and is therefore not covered.

    This document segment does not list additional specific tests or indications as not covered beyond the items already called out. However, the policy emphasizes that lack of clinical justification or missing required documentation on the prior authorization form can result in denial or non-coverage.

    Background

    Genetic testing is intended for predictive, diagnostic, or prognostic purposes. Testing should be performed only when there is a reasonable expectation—based on family history, pedigree analysis, risk factors, or symptomatology—that an inherited or acquired genetic condition exists and when results are expected to directly affect medical management (treatment or surveillance). Prior to testing, providers must ensure appropriate pre-test genetic counseling by a practitioner with expertise and document how results would change patient care.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyGenetic (Genomic) Testing Coverage Criteria
    Policy CodePolicy 037
    Change TypeNo material changes
    Effective Date05/01/2026
    Last ReviewApr 23, 2026
    Next Review Date04/23/2027
    Key ActionComplete the SWHP Genetic Testing Prior Authorization Form with clinical justification and required documentation, including evidence of pre- and post-test genetic counseling.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Frequency LimitsProvider Actions & Prior AuthorizationEligibility RequirementsDefinitionsNot Covered / Not Medically NecessaryBackground

    The absence of documentation supporting medical necessity or use of an out-of-network laboratory without justification may result in member notification of out-of-pocket costs and/or denial of coverage.

    Is the patient willing to undergo any increased interventions that may result from testing?
  1. How will the results specifically impact or alter medical management of the patient?
  2. What is the cost of the test?
  3. Is multigene panel testing more cost efficient than combined single-gene testing?
  4. Requesting provider name and NPI; supplying provider name and NPI
  5. Requested genetic test(s) and list of genes for panels; ICD-10 and CPT codes
  6. Complete Medical Information section addressing the clinical justification questions
  7. Documentation Required

    Testing Order Hierarchy — prefer single-gene when appropriate

    Testing order hierarchy and panel selection: order the least complex test that will answer the clinical question. Single-gene testing is preferred when it will provide the needed diagnostic or management information. If a panel is requested, document why single-gene testing is insufficient.

    • Authorize the smallest plausible gene panel to limit variants of uncertain significance
    • Broad multi-gene panels are not medically necessary when a more focused study is available
    • If a single-gene test answers the question, it will generally be considered medically necessary
    Prior Authorization

    Panel vs Single-Test Justification

    Panel vs single-test justification: when requesting multigene panels, the PA must include evidence that multiple genes can explain the phenotype or that genes on the panel are plausible causes. The list of genes on the panel should be provided and justified. Multiple panels tested at the same time are not medically necessary.

    • Provide rationale that two or more genes are responsible for the condition or several genes could cause disease in the family
    • Include the panel gene list and explanation for choosing that panel
    • Address cost-efficiency: is a multigene panel more cost effective than multiple single-gene tests?
    Documentation Required

    Required Documentation and Pedigree

    Required documentation for PA: pre- and post-test genetic counseling documentation must accompany the request, including evidence of informed consent and a plan for post-test counseling. A three-generation pedigree must be provided where appropriate. The completed Medical Information section of the PA form must fully answer the clinical questions — incomplete or insufficient justification may result in denial.

    • Documentation must show genetic counseling by a qualified practitioner not employed by testing companies
    • Counseling documentation should include discussion of possible results, testing limitations, inheritance, penetrance, consent, and post-test plan
    • A three-generation pedigree MUST accompany requests where appropriate
    • PA must include clear explanation how results will change medical management; the statement 'is medically necessary' alone is insufficient
    • Failure to answer the form’s clinical questions or provide sufficient justification may lead to denial
    Denial Risk

    Denial Risk — Insufficient Clinical Justification

    Insufficient clinical justification is a denial trigger. Requests for non-medical genetic testing (paternity, ancestry, non-disease traits) or requests lacking documentation that results will alter management may be denied. Provide complete clinical answers on the PA form to avoid delays or denials.

    • Non-medical testing is not medically necessary and may be denied
    • If the request does not document how results will change treatment or surveillance, it may be denied
    • Ensure all clinical questions on the PA form are fully answered and supporting records attached
    RelevanceConsidered when constructing pedigrees and assessing inheritance patterns for testing decisions.
    Multigene panel definition and form requirements
    DefinitionMultigene panel: a genetic test requesting multiple genes be analyzed simultaneously; used when two or more genes may be responsible for a condition or several genes can cause related diseases.
    Form requirement — gene listIf a panel is chosen, the list of genes must be provided on the request and in accompanying documentation to explain why that particular panel was chosen.
    Panel appropriatenessMultigene panels are appropriate when multiple genes plausibly explain the disorder; the smallest plausible panel will be authorized to reduce variants of unknown significance.
    Concurrent panelsMultiple panels tested at the same time are not medically necessary.
    Genetic counseling / informed consent
    Informed consentProviders must indicate on the prior authorization form whether the patient has given informed consent to the genetic test (Yes/No).
    Genetic counseling providedProviders must indicate whether genetic counseling has been provided prior to testing (Yes/No) on the form; pre‑ and post‑test counseling documentation must accompany PA requests.
    Counselor expertiseGenetic counseling should be performed by a practitioner with expertise in the condition; documentation must include discussion of possible results, limitations, pedigree/risk assessment, and a post‑test plan.